Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Examination of influenza specific T cell responses after influenza virus challenge in individuals vaccinated with MVA-NP+M1 vaccine.

Powell TJ, Peng Y, Berthoud TK, Blais ME, Lillie PJ, Hill AV, Rowland-Jones SL, McMichael AJ, Gilbert SC, Dong T.

PLoS One. 2013 May 3;8(5):e62778. doi: 10.1371/journal.pone.0062778. Print 2013.

2.

Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.

Tao P, Luo M, Pan R, Ling D, Zhou S, Tien P, Pan Z.

Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9.

PMID:
19135483
3.

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.

Clin Infect Dis. 2012 Jul;55(1):19-25. doi: 10.1093/cid/cis327. Epub 2012 Mar 22.

4.

Towards a universal vaccine for avian influenza: protective efficacy of modified Vaccinia virus Ankara and Adenovirus vaccines expressing conserved influenza antigens in chickens challenged with low pathogenic avian influenza virus.

Boyd AC, Ruiz-Hernandez R, Peroval MY, Carson C, Balkissoon D, Staines K, Turner AV, Hill AV, Gilbert SC, Butter C.

Vaccine. 2013 Jan 11;31(4):670-5. doi: 10.1016/j.vaccine.2012.11.047. Epub 2012 Nov 28.

5.

Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1.

Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, Milicic A, Poyntz HC, Lambe T, Fletcher HA, Hill AV, Gilbert SC.

Clin Infect Dis. 2011 Jan 1;52(1):1-7. doi: 10.1093/cid/ciq015.

6.

Protective immunity against influenza in HLA-A2 transgenic mice by modified vaccinia virus Ankara vectored vaccines containing internal influenza proteins.

Di Mario G, Sciaraffia E, Facchini M, Gubinelli F, Soprana E, Panigada M, Bernasconi V, Garulli B, Siccardi A, Donatelli I, Castrucci MR.

Pathog Glob Health. 2017 Mar;111(2):76-82. doi: 10.1080/20477724.2016.1275465. Epub 2017 Jan 12.

PMID:
28079473
7.

Modified vaccinia virus Ankara encoding influenza virus hemagglutinin induces heterosubtypic immunity in macaques.

Florek NW, Weinfurter JT, Jegaskanda S, Brewoo JN, Powell TD, Young GR, Das SC, Hatta M, Broman KW, Hungnes O, Dudman SG, Kawaoka Y, Kent SJ, Stinchcomb DT, Osorio JE, Friedrich TC.

J Virol. 2014 Nov;88(22):13418-28. doi: 10.1128/JVI.01219-14. Epub 2014 Sep 10.

8.

Increased Protein Degradation Improves Influenza Virus Nucleoprotein-Specific CD8+ T Cell Activation In Vitro but Not in C57BL/6 Mice.

Altenburg AF, van de Sandt CE, van Trierum SE, De Gruyter HL, van Run PR, Fouchier RA, Roose K, Saelens X, Volz A, Sutter G, de Vries RD, Rimmelzwaan GF.

J Virol. 2016 Oct 28;90(22):10209-10219. Print 2016 Nov 15.

9.

Progress on adenovirus-vectored universal influenza vaccines.

Xiang K, Ying G, Yan Z, Shanshan Y, Lei Z, Hongjun L, Maosheng S.

Hum Vaccin Immunother. 2015;11(5):1209-22. doi: 10.1080/21645515.2015.1016674. Review.

10.

Coadministration of seasonal influenza vaccine and MVA-NP+M1 simultaneously achieves potent humoral and cell-mediated responses.

Antrobus RD, Berthoud TK, Mullarkey CE, Hoschler K, Coughlan L, Zambon M, Hill AV, Gilbert SC.

Mol Ther. 2014 Jan;22(1):233-8. doi: 10.1038/mt.2013.162. Epub 2013 Jul 8.

11.

Virus-specific T cells as correlate of (cross-)protective immunity against influenza.

Altenburg AF, Rimmelzwaan GF, de Vries RD.

Vaccine. 2015 Jan 15;33(4):500-6. doi: 10.1016/j.vaccine.2014.11.054. Epub 2014 Dec 9. Review.

PMID:
25498210
12.

Influenza A virus matrix protein 1-specific human CD8+ T-cell response induced in trivalent inactivated vaccine recipients.

Terajima M, Cruz J, Leporati AM, Orphin L, Babon JA, Co MD, Pazoles P, Jameson J, Ennis FA.

J Virol. 2008 Sep;82(18):9283-7. doi: 10.1128/JVI.01047-08. Epub 2008 Jul 9.

13.

A T cell-inducing influenza vaccine for the elderly: safety and immunogenicity of MVA-NP+M1 in adults aged over 50 years.

Antrobus RD, Lillie PJ, Berthoud TK, Spencer AJ, McLaren JE, Ladell K, Lambe T, Milicic A, Price DA, Hill AV, Gilbert SC.

PLoS One. 2012;7(10):e48322. doi: 10.1371/journal.pone.0048322. Epub 2012 Oct 31.

14.

Activation of cross-reactive mucosal T and B cell responses in human nasopharynx-associated lymphoid tissue in vitro by Modified Vaccinia Ankara-vectored influenza vaccines.

Mullin J, Ahmed MS, Sharma R, Upile N, Beer H, Achar P, Puksuriwong S, Ferrara F, Temperton N, McNamara P, Lambe T, Gilbert SC, Zhang Q.

Vaccine. 2016 Mar 29;34(14):1688-95. doi: 10.1016/j.vaccine.2016.02.028. Epub 2016 Feb 20.

PMID:
26902548
15.

Further protection against antigenic drift of influenza virus in a ferret model by DNA vaccination.

Donnelly JJ, Friedman A, Ulmer JB, Liu MA.

Vaccine. 1997 Jun;15(8):865-8.

PMID:
9234535
16.

A human multi-epitope recombinant vaccinia virus as a universal T cell vaccine candidate against influenza virus.

Goodman AG, Heinen PP, Guerra S, Vijayan A, Sorzano CO, Gomez CE, Esteban M.

PLoS One. 2011;6(10):e25938. doi: 10.1371/journal.pone.0025938. Epub 2011 Oct 5.

17.

The design and proof of concept for a CD8(+) T cell-based vaccine inducing cross-subtype protection against influenza A virus.

Tan AC, Deliyannis G, Bharadwaj M, Brown LE, Zeng W, Jackson DC.

Immunol Cell Biol. 2013 Jan;91(1):96-104. doi: 10.1038/icb.2012.54. Epub 2012 Nov 13.

PMID:
23146941
19.

Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus.

Donnelly JJ, Friedman A, Martinez D, Montgomery DL, Shiver JW, Motzel SL, Ulmer JB, Liu MA.

Nat Med. 1995 Jun;1(6):583-7.

PMID:
7585127
20.

Supplemental Content

Support Center